Active surveillance of low-grade prostate cancer alternative to overtreatment

February 29, 2016, Canadian Medical Association Journal

For men with low-grade prostate cancer, active surveillance—monitoring with the option to treat if the cancer worsens—is the most common management strategy at a regional diagnostic centre in Ottawa, Ontario, according to new research in CMAJ (Canadian Medical Association Journal)

"These findings represent a substantial paradigm shift in the management of low-grade prostate cancer and may represent an important reduction in the potential harm associated with overtreatment of screening-detected cancers," writes Dr. Rodney Breau, a at The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, with coauthors.

Active surveillance combines close monitoring with periodic prostate-specific antigen (PSA) measurements, digital rectal exams and biopsies. If the cancer worsens, the physician will discuss appropriate treatments with the patient.

Low-grade prostate cancer makes up between 40% and 50% of all newly diagnosed cancers. Patients with these cancers are at low risk of cancer-related death but may experience adverse effects of treatment. Active surveillance is an approach for which treatment may be delayed or completely avoided. Screening for prostate cancer is controversial, with some groups recommending against screening because of the substantial risk of over-detection and over-treatment. There are few data detailing the use of active surveillance in clinical practice.

The study included 477 men with low-grade cancer referred to the Ottawa Regional Prostate Cancer Assessment Clinic between 2008 and 2013. Of those, 210 (44%) were managed with active surveillance and 244 (51%) were treated immediately for prostate cancer. The authors observed an increase in the use of active surveillance from 32% in 2008 to 67% in 2013. Patients who were older than 70 and who had multiple health issues were more likely to receive active surveillance than younger men. Of the patients managed with active surveillance, 62 (30%) were eventually treated because of a change in their disease status.

After five years of follow-up, about 59% of patients were still being managed by active surveillance.

"Our results reinforce the concept that patient preference or anxiety does not appear to be the major factor driving progression to treatment. In the Canadian context, it seems that is a feasible management approach that patients and physicians are willing to accept," state the authors.

CMAJ published screening guidelines http://www.cmaj.ca/content/186/16/1225 from the Canadian Task for on Preventive Health Care in late 2014.

Explore further: Low-risk prostate cancer best managed with active surveillance, according to new recommendations

More information: "Active surveillance in Canadian men with low-grade prostate cancer," Canadian Medical Association Journal (2016). DOI: 10.1503/cmaj.150832

Related Stories

Low-risk prostate cancer best managed with active surveillance, according to new recommendations

February 18, 2016
For most men with low-risk prostate cancer, the recommended strategy is active surveillance with regular testing to check for cancer growth rather than immediate treatment, according to guidelines from the American Society ...

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

February 24, 2015
An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients ...

Too few prostate cancer patients receiving active surveillance

July 1, 2015
(HealthDay)—A majority of U.S. men with low-risk prostate cancer who are eligible for active surveillance still undergo treatment, according to a new report published online June 29 in JAMA Internal Medicine.

New prostate cancer screening review article advocates for active surveillance

September 17, 2015
In the wake of changing guidelines related to prostate cancer screening, a newly published review article out of University Hospitals Case Medical Center's Seidman Cancer Center in Cleveland provides important guidance about ...

Men who forgo aggressive treatment for prostate cancer don't receive appropriate monitoring

December 1, 2015
An increasing number of men diagnosed with low-risk prostate cancer are opting for active surveillance - closely monitoring their cancer - rather than aggressive treatment to avoid the debilitating potential side effects ...

Prostate cancer surveillance criteria may not be accurate for African American men

January 4, 2016
A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) ...

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.